Effectiveness and Safety of Oral Chinese Patent Medicines Combined with Chemotherapy for Gastric Cancer: A Bayesian Network Meta-Analysis

Table 2

Network meta-analysis results of objective response rate (upper right quarter) and performance status (lower left quarter).

ATK + C	1.87 (0.47, 7.30)	0.58 (0.24, 1.39)	1.60 (0.62, 4.21)	0.99 (0.36, 2.55)	0.69 (0.14, 3.18)	1.27 (0.47, 3.58)	1.19 (0.37, 3.79)
–	BZ + C	0.31 (0.11, 0.87)	0.86 (0.29, 2.60)	0.53 (0.17, 1.59)	0.38 (0.07, 1.77)	0.69 (0.22, 2.20)	0.63 (0.16, 2.27)
2.13 (0.76, 6.30)	—	C	2.78 (1.97, 3.95)	1.69 (1.13, 2.56)	1.20 (0.33, 4.10)	2.20 (1.37, 3.77)	2.04 (0.97, 4.33)
0.71 (0.23, 2.33)	—	0.33 (0.21, 0.51)	HCS + C	0.61 (0.35, 1.04)	0.43 (0.12, 1.53)	0.79 (0.44, 1.48)	0.73 (0.33, 1.67)
0.59 (0.11, 2.85)	—	0.27 (0.07, 0.91)	0.81 (0.19, 3.01)	PX + C	0.70 (0.19, 2.58)	1.30 (0.70, 2.57)	1.21 (0.50, 2.85)
0.65 (0.12, 3.91)	—	0.31 (0.08, 1.16)	0.91 (0.22, 3.71)	1.14 (0.18, 7.65)	SQSYW + C	1.83 (0.49, 7.51)	1.71 (0.38, 7.20)
0.06 (0.01, 0.39)	—	0.03 (0.00, 0.12)	0.09 (0.01, 0.40)	0.11 (0.01, 0.80)	0.09 (0.01, 0.73)	XAP + C	0.92 (0.37, 2.25)
0.62 (0.14, 2.59)	—	0.28 (0.10, 0.77)	0.84 (0.28, 2.61)	1.09 (0.22, 5.76)	0.97 (0.16, 5.09)	10.12 (1.59, 85.37)	ZQFZ + C

The values in italics indicate there is a significant difference between the two groups.